Drug Trial News

RSS

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Amakem NV, a kinase platform company focusing on ophthalmology, today announces that it has initiated a Phase 2a proof of concept study of its novel Rho Kinase (ROCK) inhibitor, AMA0076, in patients with glaucoma and ocular hypertension.

27 Sep 2012

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Boehringer Ingelheim Pharmaceuticals, Inc. announced that clinical trial enrollment has completed for two phase III studies evaluating the safety and efficacy of nintedanib (BIBF 1120), an investigational compound, in patients with idiopathic pulmonary fibrosis (IPF), being studied at a twice-daily oral dose.

27 Sep 2012

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Biogen Idec and Swedish Orphan Biovitrum (Sobi) today announced positive results from B-LONG, a clinical study that evaluated a new long-lasting clotting factor candidate in people with hemophilia B. Hemophilia B is a rare inherited disorder that impairs blood coagulation.

27 Sep 2012

Antibiotic therapy can effectively treat acute appendicitis

Although the standard approach to acute appendicitis is to remove the appendix, a study at the Sahlgrenska Academy, University of Gothenburg, Sweden, reveals that treatment with antibiotics can be just as effective in many cases.

27 Sep 2012

Enrollment complete in Resverlogix‘s RVX-208 Phase 2b trial on cardiovascular disease

Resverlogix Corp. today announced that it has completed enrollment in ASSURE, a Phase 2b clinical trial targeting high-risk cardiovascular disease patients.

27 Sep 2012

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

NOXXON Pharma today announced the treatment of the first cohort of three multiple myeloma (MM) patients in a Phase IIa clinical trial of its anti-CXCL12/SDF-1 (CXC chemokine ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer NOX-A12.

26 Sep 2012

Dexamethasone use during tonsillectomy not associated with excessive bleeding in children

Tonsillectomy is exceedingly common, with a reported increase in tonsillectomy rates in children younger than 15 years from 287,000 to 530,000 per year over the past decade. Although safe, adenotonsillectomy can result in significant complications, such as aspiration and bleeding. Complications are infrequent, but because tonsillectomy is so common, the absolute number of children experiencing tonsillectomy complications is formidable.

26 Sep 2012

Lonafarnib clinical trial for progeria has scientific roots in basic biology discoveries

The good news widely reported this morning of positive results from a clinical drug trial at Boston Children's Hospital for the previously "untreatable" rapid aging disorder in children known as progeria has its scientific roots in basic biology discoveries made in recent years.

26 Sep 2012

PsiOxus initiates ColoAd1 phase I/II trial in metastatic solid tumours

PsiOxus Therapeutics, Ltd. has treated the first patient in its phase I/II clinical trial of ColoAd1for the treatment of metastatic solid tumours.

26 Sep 2012

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Researchers at University of California, San Diego Moores Cancer Center are evaluating the safety and tolerability of a synthetic cannabinoid called dexanabinol (ETS2101). Delivered as a weekly intravenous infusion, the drug is being tested in patients with all forms of brain cancer, both primary and metastatic.

26 Sep 2012

Positive results from Antares Pharma’s VIBEX MTX clinical study on rheumatoid arthritis

Antares Pharma, Inc. today announced positive results from an Actual Human Use (AHU) study for VIBEX Methotrexate (MTX).

25 Sep 2012

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced that it has established the University of Washington (UW) as the second enrolling site for its Phase II metastatic melanoma clinical trial (OMS-I100).

25 Sep 2012

Chronic respiratory disease treatments: an interview with Dr Sven Jan-Anders Karlsson, CEO of Verona Pharma

There are many different chronic respiratory diseases. Verona Pharma is mainly focused on two diseases: asthma and COPD. Asthma is a very common disease and unfortunately it has been increasing in prevalence in developed countries. This is the same with COPD; however, there may be different reasons for this.

25 Sep 2012

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Researchers have launched a clinical trial to evaluate the drug candidate DEX-M74 as a treatment for a rare degenerative muscle disease, hereditary inclusion body myopathy (HIBM). National Institutes of Health scientists from the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI) will conduct the clinical trial at the NIH Clinical Center.

25 Sep 2012

Lonafarnib proves effective for children with progeria

Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.

25 Sep 2012

Study to examine SYMPLICITY renal denervation system for treatment-resistant hypertension

The University of Michigan Cardiovascular Center will participate in a national clinical trial to treat the most challenging form of high blood pressure.

24 Sep 2012

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that dosing with their first drug in its first Phase 1 study, was completed last week.

24 Sep 2012

Sanofi chooses OnPoint clinical trial management system from BioClinica

BioClinica, Inc., a global provider of clinical trial management services, announced today that Sanofi, one of the world's largest pharmaceutical companies, has selected BioClinica's OnPoint as the company's standard CTMS (Clinical Trial Management System).

From Clario 24 Sep 2012

$Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma$

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Cell Therapeutics, Inc. announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma.

24 Sep 2012

Drug Trial News

Amakem commences AMA0076 Phase 2a study in glaucoma and ocular hypertension

Enrollment complete in Boehringer Ingelheim’s nintedanib phase III studies for IPF

Positive results from Sobi, Biogen Idec's rFIXFc Phase 3 trial on hemophilia B

Antibiotic therapy can effectively treat acute appendicitis

Enrollment complete in Resverlogix‘s RVX-208 Phase 2b trial on cardiovascular disease

NOXXON commences NOX-A12 Phase IIa trial in relapsed MM

Dexamethasone use during tonsillectomy not associated with excessive bleeding in children

Lonafarnib clinical trial for progeria has scientific roots in basic biology discoveries

PsiOxus initiates ColoAd1 phase I/II trial in metastatic solid tumours

UCSD evaluates safety and tolerability of dexanabinol in Phase I brain cancer study

Positive results from Antares Pharma’s VIBEX MTX clinical study on rheumatoid arthritis

OncoSec establishes UW as second enrolling site for OMS-I100 Phase II metastatic melanoma trial

Chronic respiratory disease treatments: an interview with Dr Sven Jan-Anders Karlsson, CEO of Verona Pharma

New clinical trial to evaluate DEX-M74 against hereditary inclusion body myopathy

Lonafarnib proves effective for children with progeria

Study to examine SYMPLICITY renal denervation system for treatment-resistant hypertension

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

Sanofi chooses OnPoint clinical trial management system from BioClinica

Encouraging results from CTI’s pacritinib phase 1 study on relapsed/refractory lymphoma

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News